PRO 155

Drug Profile

PRO 155

Alternative Names: PRO-155

Latest Information Update: 09 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Laboratorios Sophia
  • Class Eye disorder therapies; Nonsteroidal anti-inflammatories
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ocular inflammation

Most Recent Events

  • 01 Dec 2013 Phase-II clinical trials in Ocular inflammation in Mexico (Ophthalmic)
  • 03 Aug 2012 Laboratorios Sophia plans a phase II trial for Ocular inflammation in Mexico (NCT01657266)
  • 24 Feb 2012 Laboratorios Sophia completes enrolment in its phase I trial in Healthy volunteers in Mexico (NCT01535443)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top